Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2015-08-07 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2015-08-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement of the approval of a drug product in Canada, which is an 'Other Event' under Item 8.01. There are no financial statements or detailed financial data included, and the document is relatively short (2881 characters). It also includes a press release as an exhibit. This type of filing is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-08-06 English
10-Q
Interim / Quarterly Report Q2 2015
2015-08-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 24, 2015, reporting on two main items: (1) Results of Operations and Financial Condition for the quarter ended June 30, 2015, including a press release and conference call announcement, and (2) an amendment to the company's 2009 Severance Plan approved by the Compensation Committee. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The 8-K is a current report used to announce material events and updates rather than a full quarterly or annual report. The presence of a press release about quarterly results aligns with an Earnings Release (ER) filing, which is typically the initial announcement of quarterly financial results. The document is about 5,047 characters, which is consistent with a brief announcement rather than a full report. Therefore, the best classification is Earnings Release (ER).
2015-07-29 English
4
Director's Dealing
2015-07-28 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from Theravance, Inc. responding to a comment from the SEC staff regarding their Form 10-K filing for the fiscal year ended December 31, 2014. The letter discusses patent disclosures related to the 10-K but does not contain the 10-K report itself. It is a correspondence addressing SEC comments on the 10-K, not the full annual report. The document length is about 5700 characters, which is relatively short and consistent with a comment response letter rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence related to the 10-K filing, not the 10-K report itself.
2015-07-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.